SCHEMBL1892950

SCHEMBL1892950

CC(C(N)=O)c1cccc(C(=O)C2CCCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.43
PTGS2 P35354 3/20 0.43
MAPT P10636 2/20 0.43
CXCR1 P25024 2/20 0.43
CXCR2 P25025 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 2/20 0.43
RECQL P46063 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
PMP22 Q01453 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CXCL8 P10145 1/20 0.43
THPO P40225 1/20 0.43
HIF1A Q16665 1/20 0.43
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887457 1.00 PTGS1 (0.43) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL26610223 0.87 PTGS1 (0.59) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL1907869 0.82 KDM4E (0.42) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL3685970 0.81 PTGS1 (0.62) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL1885903 0.79 KDM4E (0.44) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL1886979 0.77 POLB (0.60) MAPTLMNAKDM4EALDH1A1CYP3A4
SCHEMBL13952701 0.77 POLB (0.60) MAPTLMNAKDM4EALDH1A1CYP3A4
SCHEMBL1890332 0.76 RAB9A (0.51) MAPTSMN1; SMN2LMNAALDH1A1KMT2A
SCHEMBL1886309 0.75 MAPT (0.50) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL1886312 0.75 MAPT (0.50) PTGS1PTGS2MAPTCXCR1CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939521-B2 2-arylpropionic acid derivatives and pharmaceutical compositions containing them DompePHA.R.MA S.p.A. (IT) 2011-05-10 US disclosed
EP-1856031-B1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-02-25 EP disclosed
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them DOMPE' PHA.R.MA.S.P.A. (IT) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them C3AR1, C5AR2, C5AR1 PTGS1 197/4885PTGS2 137/4885MAPT 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.